Aug. 27 at 9:07 PM
$ABEO Abeona Therapeutics is eligible to receive up to
$30 million in commercial milestone payments tied to the regulatory approval and success of UX111 (rebisufligene etisparvovec), alongside tiered royalties of up to 10% on net sales.Financial Agreement OverviewMilestone Payments: Up to
$30 million in regulatory and commercial milestone payments from partner Ultragenyx Royalties: Tiered royalties of up to 10% on global net sales of UX111.Operational Role: Abeona holds a strictly financial interest in the asset, as the program was out-licensed to Ultragenyx, which manages development, regulatory filings, and commercialization."
SEEMS TO ME that if UX111 gets approved and ABEO can get up to
$30M in milestone payments and up to 10% of sales without any overhead expenses, it should be worth quite a bit in share price increase. It also would take ABEO out of the one trick pony category and several other things coming. Makes the share price more undervalued than it already is.
